Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRDPTF EV-to-OCF is -0.06 as of Jul. 31, 2026. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Radiopharm Theranostics ranks worse than 70.92% on this metric.
The historical rank and industry rank for Radiopharm Theranostics's EV-to-OCF or its related term are showing as below:
RDPTF'
s EV-to-OCF Range Over the Past 10 Years
Min: -1.25 Med: -0.29 Max: 0.49
Current: -0.06
During the past 4 years, the highest EV-to-OCF of Radiopharm Theranostics was 0.49. The lowest was -1.25. And the median was -0.29.
RDPTF's EV-to-OCF is ranked worse than 70.92% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs RDPTF: -0.06
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Radiopharm Theranostics's PE Ratio (TTM) for today is calculated as:
Radiopharm Theranostics's share price for today is $0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's EV-to-OCF falls into.
Radiopharm Theranostics's current Enterprise Value is $1.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-23.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (RDPTF) has a EV-to-OCF of -0.06 as of Jul. 31, 2026. According to the industry distribution chart, Radiopharm Theranostics ranks #1000 out of 1410 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Radiopharm Theranostics' EV-to-OCF too high?
Radiopharm Theranostics' current EV-to-OCF is -0.06. Based on the distribution chart, Radiopharm Theranostics ranks #1000 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint.
How does Radiopharm Theranostics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #1000 out of 1410 companies for EV-to-OCF. This places Radiopharm Theranostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Radiopharm Theranostics's current EV-to-OCF is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current EV-to-OCF of -0.06. The current EV-to-OCF is -0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current EV-to-OCF is -0.06 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDPTF has been successfully added to your 
